Group 1 - The company, Guocera Materials, plans to acquire 100% equity of Australian listed company SDI Limited for a total investment of approximately 81.58 million RMB, at a price of 1.40 AUD per share [1] - The acquisition is part of the company's strategic development and international business planning [1] - The agreement for the equity transfer was signed on February 27, 2026, and the company will hold 100% of the target company post-acquisition [1] Group 2 - SDI Limited, established in 1972 and headquartered in Melbourne, Australia, is a leading manufacturer and global distributor in the dental materials sector [2] - The company specializes in the research, production, and sales of various restorative dental products, targeting clinical end-users [2] - SDI's product offerings include aesthetic restorative materials, professional teeth whitening materials, silver amalgam materials, and associated specialized equipment, with all products manufactured in Victoria, Australia, and distributed to over 100 countries and regions worldwide [2]

Group 1 - The core point of the article is that Dah Sing Financial (00440.HK) has entered into a purchase agreement to acquire properties from Reward Investment Limited for a total consideration of HKD 839 million [1] - The properties to be acquired include an entire ground floor retail space and multiple floors (6th to 12th, 15th, 17th, and 18th) of a building, along with rights to change the building's name and signage [1] - The acquisition also includes five advertising units on the building's exterior and 20 parking spaces [1]

Group 1 - The core point of the article is the appointment of Zhang Zhihui as the chairman of the sixth board of directors of Qin Port Co., Ltd. [1]

| 股份代號: | 01138 | | --- | --- | | 上市法國名稱: | 中遠海運能源運輸股份有限公司 | | 日期 (日 / 月 / 年): | 27/01/2026 - 27/02/2026 | | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | 持有權益的投分數目 | 佔已發行的 有關事 | | --- | --- | --- | --- | --- | | | 10 5 5 三 | | | (請參閱上述*註解) 有投票權股 (日 / F | | | | | | 给自分明 | | Companies and CS20260227E00188 | Pacific Asset Management Co., 1201(L) | 7,394,000(L) | HKD 19.0300 109,260,000(L) | 8.43(L)25/02/2 | | | LIO | | | | 格隆汇2月27日丨根据联交所最新权益披露资料显示，2026年2月25日，中远海能(01138.HK)遭Pacific Asset Management Co., ...

Group 1 - The core viewpoint of the article is that Henghe Group (00513.HK) reported a significant decline in comprehensive income for the six months ending December 31, 2025, primarily due to reduced property sales [1] - The comprehensive income decreased by approximately HKD 107,511,000 or 32.64%, from HKD 329,326,000 in the previous interim period to HKD 221,815,000 [1] - The company reported a profit attributable to shareholders of HKD 34,000, compared to a loss of HKD 16,968,000 in the same period last year [1] Group 2 - The basic earnings per share for the six months ending December 31, 2025, was HKD 0.01, compared to a basic loss per share of HKD 2.48 in 2024 [1]

格隆汇2月27日丨寒武纪(688256.SH)公布2025年度业绩快报，报告期内，公司实现营业收入64.97亿元， 同比增长453.21%。报告期内，公司归属于母公司所有者的净利润为20.59亿元，较上年同期扭亏为盈， 主要系本期营业收入大幅增长所致。 公司营业总收入较上年同期增长453.21%，报告期内，受益于人工智能行业算力需求的持续攀升，公司 凭借产品的优异竞争力持续拓展市场，积极推动人工智能应用场景落地，使得本期收入规模较上年同期 大幅增长。 ...

Core Insights - The company reported a revenue of 1.218 billion yuan for the fiscal year 2025, representing a year-on-year growth of 12.92% [1] - The net profit attributable to the parent company was 196 million yuan, with a year-on-year increase of 10.53% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 184 million yuan, reflecting an 11.52% year-on-year growth [1] Group 1: Revenue and Profit Growth - The company's revenue and profit achieved steady growth, driven by the deep layout of its innovative drug pipeline, realization of value from licensing collaborations, and support from an integrated service model [1] - The innovative drug pipeline focuses on research and development of drugs with global independent intellectual property rights, covering cutting-edge fields such as peptides, small nucleic acids, cell, and gene therapy [1] - The company has established a pipeline matrix that includes over 20 first-class new drugs targeting major diseases such as cancer and pain [1] Group 2: Clinical and Operational Efficiency - The company efficiently promotes R&D projects through a "preclinical + clinical" integrated service model, supported by a comprehensive quality management system and a clinical cooperation network with over 300 hospitals [1] - Core pipelines like STC007 and STC008 have successfully entered critical clinical stages, providing stable income through R&D services and laying the foundation for long-term value release [1] - The integration of unique technology platforms like iCVETide with AI technology further enhances the company's core competitiveness and accelerates the advancement of its R&D pipeline [1] Group 3: Profit Growth Drivers - Licensing collaborations and revenue sharing have become key drivers of profit growth, with significant income generated from the licensing of pipelines such as STC007 and STC008, forming a high-margin revenue source [2] - The implementation of the "R&D services + pipeline cultivation + new quality industrial chain" strategy provides solid support for business growth, steadily improving the company's profitability [2]

Core Insights - The global open day event held by Lijin Technology (0558.HK) in Thailand focused on die-casting, injection molding, and CNC machining solutions, attracting hundreds of ASEAN customers and partners [1] - The event resulted in multiple on-site contracts, including spot purchases and future orders, particularly from clients in the automotive parts, 3C electronics, and bathroom hardware sectors [1] - Lijin has been rooted in Thailand for 19 years, having established a subsidiary in 2007, and is set to expand its factory in Spring Hill in 2024 to enhance spare parts storage and service response capabilities [1] - The company introduced several specialized models tailored to the ASEAN market during the event, emphasizing its strategy of "technology empowerment + localized service" [1] - The open day served not only as a product showcase but also as a practical implementation of Lijin's strategy to strengthen its regional market position and contribute to the high-quality development of ASEAN manufacturing [1]

Core Viewpoint - Semir Holdings (00756.HK) reported a slight revenue decline of approximately 6.2% for the six months ending December 31, 2025, with revenue around RMB 34,406 million compared to RMB 36,687 million in 2024 [1] Financial Performance - The company experienced a net loss of approximately RMB 12.95 million for the reporting period, an improvement from a net loss of about RMB 26.47 million in 2024 [1] Market Environment - The company faced challenging times due to an uncertain global economic outlook, which continues to create a difficult business environment for the upcoming year [1] - The company plans to focus on producing frozen concentrated orange juice and non-reduced orange juice, promoting sales to juice trading companies [1]

格隆汇2月27日丨申万宏源(06806.HK)公告， 2026年2月26日，申万宏源证券有限公司2026年面向专业 投资者公开发行短期公司债券(第二期)(以下简称"本期债券")完成发行工作。本期债券发行规模人民币 11亿元，其中品种一发行规模人民币5亿元，期限190天，票面利率为1.64%；品种二发行规模人民币6 亿元，期限365天，票面利率为1.65%。本期债券登记完成后拟于深圳证券交易所上市交易。 ...